Dharminder Singh Chahal

Spatium Medical is bringing responsive, ventilation-adjusted and patient-tailored insufflation to the field of laparoscopy. Developed by clinicians and researchers at Erasmus MC in Rotterdam, The Netherlands and the TechRes Lab in Milan, Italy, these innovative technologies enable us to improve patient recovery and surgical outcome in laparoscopic surgeries. Spatium Medical was founded to provide surgeons with next-generation technologies that improve the lives of patients worldwide.

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Sensara provides data driven inisghts to caretakers so that they can deliver the best quality of care.

De uiteindelijke missie is om MS als ziekte tenminste chronisch te maken door zo snel mogelijk het verloop / de progressie van de ziekte te stoppen en mensen met MS beter te laten functioneren zodat zij zo volwaardig mogelijk kunnen (blijven) participeren in het gezin en de maatschappij. Dit kan enerzijds door het subsidiëren van veelbelovend (medisch wetenschappelijk) onderzoek in (inter)nationale wetenschappelijke instituten, (academische) ziekenhuizen of andere (zorg)instellingen. Anderzijds kan de stichting ook (startende) ondernemingen die werkzaam zijn in het MS-veld financieel ondersteunen om innovatieve medische of technische interventies sneller bij de patiënt te krijgen. Daarnaast bestaat de wens om op de kortere termijn de omgeving van de patiënt aan te passen en te verbeteren waardoor de kwaliteit van leven in de progressieve en gevorderde fase van de ziekte voor patiënt en familie wordt verhoogd middels bijvoorbeeld respijtzorg initiatieven ofwel door het ontwikkelen van meer geschikte hulpmiddelen.

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com.

Isobionics® Natural Ingredients focuses its activities on natural raw materials for the flavour and fragrance industry. These are produced with an innovative fermentation process, resulting in high quality natural products for our customers in the food, beverage, flavour and fragrance market. Our proprietary technology is environmentally friendly, uses less production steps and is easier to scale up. This results in a constant quality and stable pricing. Our products have a high purity and the production is harvest independent, resulting in a constant availability. Our vision is to provide value to our customers by delivering a range of high quality products supported by excellent customer service and to create a leading position by developing innovative new products and processes within a sustainable sourcing strategy. Our research and development team, aiming for the highest standard of production, ensures our customers world-class highly reliable products in order to boost their success.

Spatium Medical is bringing responsive, ventilation-adjusted and patient-tailored insufflation to the field of laparoscopy. Developed by clinicians and researchers at Erasmus MC in Rotterdam, The Netherlands and the TechRes Lab in Milan, Italy, these innovative technologies enable us to improve patient recovery and surgical outcome in laparoscopic surgeries. Spatium Medical was founded to provide surgeons with next-generation technologies that improve the lives of patients worldwide.

Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.

Allero Therapeutics is a Dutch biotech company that develops next generation immunotherapies for immune mediated disorders. Our goal is to develop novel targeted treatments that induce long-lasting antigen-specific tolerance. Our proprietary SOMIT (Specific Oromucosal Immunotherapy) technology combines a tolerance-inducing agent with novel oral patch mediated targeted delivery of specific antigens to the oral mucosa immune privilege.

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Medis medical imaging systems bv is a leading provider of innovative software solutions that enable clinicians, technicians and researchers to accurately quantify medical images. Medis produces and markets software solutions for cardiovascular imaging that cover the modalities MRI, CT, X-ray angiography and intravascular ultrasound. Since its foundation in 1989, Medis has introduced a range of quantification software solutions that have proven their value in clinical practice and research. QAngio® XA and QMass® MR are Medis'​ flagship products. QAngio® XA incorporates the module QCA-CMS™, which is widely considered as a best-in-class solution for the quantification of coronary vessels. QMass® MR is used by clinicians and core labs worldwide to help assess cardiac function. Medis'​ corporate headquarters are located in Leiden, the Netherlands, and the company has a subsidiaries in: Raleigh, NC, USA Birmingham, United Kingdom Toronto, ON, Canada Tokyo, Japan